BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22149631)

  • 21. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia.
    Ezat WP; Aljunid S
    Asian Pac J Cancer Prev; 2010; 11(1):79-90. PubMed ID: 20593935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of HPV vaccination: comparing the general population with socially vulnerable individuals.
    Han KT; Kim SJ; Lee SY; Park EC
    Asian Pac J Cancer Prev; 2014; 15(19):8503-8. PubMed ID: 25339055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.
    Zou Z; Fairley CK; Ong JJ; Hocking J; Canfell K; Ma X; Chow EPF; Xu X; Zhang L; Zhuang G
    Lancet Glob Health; 2020 Oct; 8(10):e1335-e1344. PubMed ID: 32971056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
    Setiawan D; Andrijono ; Hadinegoro SR; Meyta H; Sitohang RV; Tandy G; Perwitasari DA; Postma MJ
    PLoS One; 2020; 15(3):e0230359. PubMed ID: 32203527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
    Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.
    Praditsitthikorn N; Teerawattananon Y; Tantivess S; Limwattananon S; Riewpaiboon A; Chichareon S; Ieumwananonthachai N; Tangcharoensathien V
    Pharmacoeconomics; 2011 Sep; 29(9):781-806. PubMed ID: 21838332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands.
    Luttjeboer J; Setiawan D; Cao Q; Cahh Daemen T; Postma MJ
    Vaccine; 2016 Dec; 34(50):6381-6387. PubMed ID: 27816370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
    BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
    Goldie SJ; Kohli M; Grima D; Weinstein MC; Wright TC; Bosch FX; Franco E
    J Natl Cancer Inst; 2004 Apr; 96(8):604-15. PubMed ID: 15100338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X; Stander MP; Van Kriekinge G; Demarteau N
    BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
    Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
    Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
    Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J
    Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
    Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
    BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methods of model calibration: observations from a mathematical model of cervical cancer.
    Taylor DC; Pawar V; Kruzikas D; Gilmore KE; Pandya A; Iskandar R; Weinstein MC
    Pharmacoeconomics; 2010; 28(11):995-1000. PubMed ID: 20936883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM; van Ballegooijen M; Habbema JD
    J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis.
    Choi HCW; Jit M; Leung GM; Tsui KL; Wu JT
    BMC Med; 2018 Aug; 16(1):127. PubMed ID: 30115065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
    Lee VJ; Tay SK; Teoh YL; Tok MY
    BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.